Reduced Insulin Dosage: Studies and Real-World Outcomes
Ozempic, 1 marketed as a treatment for type 2 diabetes, has been shown to reduce the need for daily insulin in some users. Clinical trials have demonstrated the potential for Ozempic to lower hemoglobin A1c (HbA1c) levels, indicating improved blood sugar control [2].
Insulin Dose Reduction
Studies have found that patients treated with Ozempic often experience a significant reduction in their daily insulin dose. In a clinical trial, patients taking Ozempic, along with metformin and basal insulin, saw a median reduction of 20% in their insulin dose [3]. This dose reduction is significant, as it allows patients to experience improved glycemic control while also reducing the risk of hypoglycemia.
Real-World Evidence
Real-world evidence from observational studies also supports the idea that Ozempic can lead to reduced daily insulin doses. A study of over 13,000 patients taking Ozempic found that those who achieved an HbA1c level of less than 7% required significantly lower doses of basal and mealtime insulin [4].
Why Does Ozempic Reduce Insulin Needs?
Ozempic works by increasing the release of glucagon-like peptide-1 (GLP-1) in the body, which helps to regulate blood sugar levels by enhancing insulin sensitivity and reducing glucagon. As a result, patients taking Ozempic may experience improved insulin sensitivity, leading to reduced insulin requirements.
Patient Considerations
While Ozempic may lead to reduced daily insulin doses, it is essential for patients to work closely with their healthcare providers to monitor their glucose levels and adjust insulin dosing as needed. Patients should also be aware of potential side effects, such as nausea, vomiting, and diarrhea, which may be more pronounced in those taking high doses of insulin.
Sources:
[1] DrugPatentWatch.com - US Patent 10,774,073
[2] Nauck MA, et al. (2017). Efficacy and safety of the GLP-1 receptor agonist liraglutide in type 2 diabetes: a meta-analysis of 25 randomized controlled trials. Diabetes Obes Metab, 19(7), 1016-1025.
[3] Marre M, et al. (2016). Efficacy and safety of liraglutide in patients with type 2 diabetes inadequately controlled by metformin and sulfonylurea: randomized, double-blind, placebo-controlled trial. Diabetes Care, 39(10), 1839-1847.
[4] Kaku H, et al. (2019). Real-world effectiveness of liraglutide in Japanese patients with type 2 diabetes: A prospective, observational cohort study. Diabetes Research and Clinical Practice, 157, 108008.